Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $7.00 at Bank of America

Sana Biotechnology (NASDAQ:SANA) had its target price boosted by analysts at Bank of America from $6.00 to $7.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 63.74% from the stock’s current price.

A number of other equities analysts also recently commented on SANA. Citizens Jmp lifted their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. HC Wainwright reduced their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. JMP Securities set a $8.00 price objective on Sana Biotechnology in a report on Thursday, October 30th. Wedbush raised their target price on Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Finally, Wall Street Zen upgraded Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

Sana Biotechnology Stock Performance

Shares of SANA stock traded up $0.22 during trading hours on Tuesday, reaching $4.28. The company had a trading volume of 1,770,929 shares, compared to its average volume of 1,989,438. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -4.41 and a beta of 1.96. The stock has a fifty day moving average of $4.32 and a 200-day moving average of $3.98.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. On average, analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors have recently modified their holdings of SANA. Marex Group plc acquired a new stake in shares of Sana Biotechnology in the second quarter valued at $10,423,000. Vanguard Group Inc. increased its holdings in Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after purchasing an additional 1,517,474 shares during the period. JPMorgan Chase & Co. raised its position in Sana Biotechnology by 180.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares in the last quarter. Baillie Gifford & Co. raised its position in Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after purchasing an additional 1,371,775 shares in the last quarter. Finally, Corient Private Wealth LLC boosted its stake in shares of Sana Biotechnology by 264.7% in the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after buying an additional 824,505 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.